Skip Navigation

Osteoporosis - secondary prevention (replaced by TA161)

The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women

Guidance type:  Technology appraisal
Date issued:  January 2005

We will consult on our review plans for this guidance in October 2007.
Reference:  TA87

Summary

This guidance has been replaced by TA161 Osteoporosis - secondary prevention including strontium ranelate.
Top

Documents

For healthcare professionals

  • None found

For patients, carers and the public

  • None found

Background information

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

  • None found
Top

Search NICE guidance


Advanced guidance search

Related guidance

Click the links below to see guidance on similar topics

Order NICE guidance

Order printed copies of our guidance